Press Releases Press Releases Keyword Search Year None20232022202120202019201820172016201520142013 26 Sep '2023 XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke 30 Aug '2023 XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer 08 Aug '2023 XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial 22 May '2023 FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients 17 May '2023 XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares 17 Apr '2023 XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Press Releases Keyword Search Year None20232022202120202019201820172016201520142013 26 Sep '2023 XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke 30 Aug '2023 XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer 08 Aug '2023 XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial 22 May '2023 FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients 17 May '2023 XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares 17 Apr '2023 XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
26 Sep '2023 XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
30 Aug '2023 XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
08 Aug '2023 XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
17 Apr '2023 XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
